Ausgabe 3/2015
Inhalt (23 Artikel)
VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis
Lucas Vieira dos Santos, Marcelo Rocha Cruz, Gilberto de Lima Lopes, Joao Paulo da Silveira Nogueira Lima
Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival
Lingeng Lu, Hongmei Zeng, Xinsheng Gu, Wenxue Ma
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
Delphine R. Boulbes, Gaurav B. Chauhan, Quanri Jin, Chandra Bartholomeusz, Francisco J. Esteva
Relevance of βGal–βGalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients
Karin Milde-Langosch, Dina Schütze, Leticia Oliveira-Ferrer, Harriet Wikman, Volkmar Müller, Patrick Lebok, Klaus Pantel, Christine Schröder, Isabell Witzel, Udo Schumacher
Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing
Yong Wu, Marianna Sarkissyan, Eva Mcghee, Sangkyu Lee, Jaydutt V. Vadgama
Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer
Shaham Beg, Abdul K. Siraj, Sarita Prabhakaran, Zeenath Jehan, Dahish Ajarim, Fouad Al-Dayel, Asma Tulbah, Khawla S. Al-Kuraya
Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer
Hua Zhang, Nicos Angelopoulos, Yichen Xu, Arnhild Grothey, Joao Nunes, Justin Stebbing, Georgios Giamas
Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer
Christoph Scholz, U. Andergassen, P. Hepp, C. Schindlbeck, Thomas W. P. Friedl, N. Harbeck, M. Kiechle, H. Sommer, H. Hauner, K. Friese, B. Rack, W. Janni
Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis
Ginés Luengo-Gil, Enrique González-Billalabeitia, Asunción Chaves-Benito, Elena García Martínez, Elisa García Garre, Vicente Vicente, Francisco Ayala de la Peña
Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)
Kathryn J. Ruddy, Hao Guo, William Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth A. Overmoyer, Clifford Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer, Ann H. Partridge, Sara M. Tolaney
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
Miguel J. Gil-Gil, M. Bellet, S. Morales, B. Ojeda, L. Manso, C. Mesia, E. Garcia-Martínez, N. Martinez-Jáñez, M. Melé, A. Llombart, S. Pernas, P. Villagrasa, C. Blasco, J. Baselga
Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer
Rong Liu, Qiao-Li Lv, Jing Yu, Lei Hu, Li-Hua Zhang, Yu Cheng, Hong-Hao Zhou
Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes
Hee Jin Lee, Jeong-Ju Lee, In Hye Song, In Ah Park, Jun Kang, Jong Han Yu, Jin-Hee Ahn, Gyungyub Gong
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
Virginia G. Kaklamani, Jacqueline S. Jeruss, Elisha Hughes, Kalliopi Siziopikou, Kirsten M. Timms, Alexander Gutin, Victor Abkevich, Zaina Sangale, Cara Solimeno, Krystal L. Brown, Joshua Jones, Anne-Renee Hartman, Caitlin Meservey, Borko Jovanovic, Irene Helenowski, Seema A. Khan, Kevin Bethke, Nora Hansen, Regina Uthe, Sara Giordano, Steven Rosen, Kent Hoskins, Jamie Von Roenn, Sarika Jain, Vamsi Parini, William Gradishar
Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis
William W. L. Wong, Lisa K. Hicks, Hong-Anh Tu, Kathleen I. Pritchard, Murray D. Krahn, Jordan J. Feld, Kelvin K. Chan
Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry
Tehillah S. Menes, Mary Beth Terry, David Goldgar, Irene L. Andrulis, Julia A. Knight, Esther M. John, Yuyan Liao, Melissa Southey, Alexander Miron, Wendy Chung, Saundra S. Buys
Digoxin use after diagnosis of breast cancer and survival: a population-based cohort study
Reema A. Karasneh, Liam J. Murray, Úna C. Mc Menamin, Carmel M. Hughes, Chris R. Cardwell
TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li–Fraumeni family
Sonja Kappel, Elisabeth Janschek, Brigitte Wolf, Margaretha Rudas, Bela Teleky, Raimund Jakesz, Daniela Kandioler
Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients
Patricia J. Hollen, Pavlos Msaouel, Richard J. Gralla
Racial and ethnic differences in risk of second primary cancers among breast cancer survivors
Gregory S. Calip, Ernest H. Law, Naomi Y. Ko
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
Ines Vaz-Luis, Nancy U. Lin, Nancy L. Keating, William T. Barry, Huichuan Lii, Eric P. Winer, Rachel A. Freedman
Status of estrogen receptor 1 (ESR1) gene in mastopathy predicts subsequent development of breast cancer
Savas D. Soysal, Incken B. Kilic, Christian R. A. Regenbrecht, Sandra Schneider, Simone Muenst, Nerbil Kilic, Uwe Güth, Manfred Dietel, Luigi M. Terracciano, Ergin Kilic
Identification of clinically relevant alterations in phyllodes tumor of the breast by amplicon-based next-generation sequencing
Julia Y. S. Tsang, Edna May L. Go, Gary M. Tse